Breaking News, Collaborations & Alliances

Halia and Biolexis Partner to Discover Breakthrough Treatment for Neuroinflammation

Collaboration leverages AI to identify a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation.

Author Image

By: Charlie Sternberg

Associate Editor

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, and Biolexis Therapeutics, a biotechnology company, have successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis’ MolecuLern AI-enabled approach. This milestone represents a significant advancement in developing treatments for neuroinflammatory disorders, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters